Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

News SummaryMost relevantAll newsSector newsTweets

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
08/18 NOVO NORDISK A/S : ex-dividend day for interim dividend
08/17 NOVO NORDISK A/S : - Semaglutide superior to dulaglutide on glucose control and ..
08/17 ELI LILLY AND CO (NYSE : LLY) Tanks As Novo Nordisk A/S (ADR) (NYSE:NVO) Diabete..
08/16 NOVO NORDISK A/S : Semaglutide superior to dulaglutide on glucose control and we..
08/16 NOVO NORDISK A/S : Trading in Novo Nordisk Shares by Board Members, Executives a..
08/16 NOVO NORDISK A/S : - Share Repurchase Programme
08/16 NOVO NORDISK A/S : A S - Share repurchase programme
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker -2-
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker Stumbles When Customers Balk
08/15 NOVO NORDISK A/S : Changes in Novo Nordisk Executive Management
More news
News from SeekingAlpha
08/18 Novo And Lilly Head For Diabetes Pricing Battle
08/16 Novo's semaglutide beats Lilly's dulaglutide in late-stage study in type 2 di..
08/16 Emisphere's Prudent Move
08/16 Novo Nordisk goes ex-dividend tomorrow
08/15 Novo's traditional innovation model worked until it didn't - WSJ
Financials ( DKK)
Sales 2017 113 382 M
EBIT 2017 49 220 M
Net income 2017 38 214 M
Finance 2017 18 480 M
Yield 2017 2,71%
P/E ratio 2017 18,53
P/E ratio 2018 17,26
EV / Sales 2017 4,79x
EV / Sales 2018 4,61x
Capitalization 562 078 M
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 31
Average target price 288  DKK
Spread / Average Target 0,70%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S12.45%88 994
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554